Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKinsey
McKesson
Boehringer Ingelheim
AstraZeneca
Colorcon

Last Updated: November 20, 2019

DrugPatentWatch Database Preview

Litigation Details for Research Foundation of State University of New York v. Impax Laboratories Inc. (D. Del. 2009)

See Plans and Pricing

« Back to Dashboard

Research Foundation of State University of New York v. Impax Laboratories Inc. (D. Del. 2009)

Docket   Start Trial Date Filed 2009-09-18
Court District Court, D. Delaware Date Terminated 2012-08-09
Cause 35:271 Patent Infringement Assigned To Leonard Philip Stark
Jury Demand None Referred To
Parties GALDERMA LABORATORIES INC.; GALDERMA LABORATORIES LP; IMPAX LABORATORIES INC.; NEW YORK UNIVERSITY; RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
Patents 5,789,395; 5,919,775; 7,211,267; 7,232,572
Attorneys Jack B. Blumenfeld; Mary Matterer; Thomas Francis Driscoll , III
Firms Bifferato LLC; Morris, Nichols, Arsht & Tunnell
Link to Docket External link to docket
Small Molecule Drugs cited in Research Foundation of State University of New York v. Impax Laboratories Inc.
The small molecule drug covered by the patents cited in this case is   Start Trial .

Details for Research Foundation of State University of New York v. Impax Laboratories Inc. (D. Del. 2009)

Date Filed Document No. Description Snippet Link To Document
2009-09-18 1 Complaint United States Patents Nos. 7,232,572 (“the ‘572 patent”); 7,211,267 (“the ‘267 patent”); 5,789,395 (“the ‘395…‘395 patent”); and 3 5,919,775 (“the ‘775 patent”). (Exhibits A-D.) This action is based upon the Patent…assignee A copy of the ‘572 patent is attached as Exhibit A. 12. The ‘572 patent is listed in the Approved…any infringement of the ‘572 patent. 15. On May 1, 2007, the ‘267 patent, entitled “Methods of Treating…assignee. A copy of the ‘267 patent is attached as Exhibit B. 16. The ‘267 patent is listed in the Orange External link to document
2009-10-13 11 Answer to Complaint of U.S. Patents Nos. 7,232,572 (“the ‘572 patent”); 7,211,267 (“the ‘267 patent”); 5,789,395 (“the ‘395…‘395 patent”); and 5,919,775 (“the ‘775 patent”), copies of which are attached as Exhibits A-D to the …listed as assignee on the patent. lman also admits that a copy of the ‘572 patent is attached as Exhibit …listed as assignee on the patent, lmpax also admits that a copy of the ‘267 patent is attached as Exhibit…listed as assignees on the patent. lmpax also admits that a copy of the ‘395 patent is attached as Exhibit External link to document
2012-06-22 24 14, and 16 of U.S. Patent No. 5,789,395 and Claims 1, 2, 4, 5, and 9 of U.S. Patent No. 5,919,775 are …of U.S. Patent No. 7,211,267 and Claims 1, 12, 13, 14, 15, 20, 21, 23, 24, and 26 of U.S. Patent No. 7,…2009 9 August 2012 1:09-cv-00703 830 Patent None District Court, D. Delaware External link to document
2009-09-18 3 Patent/Trademark Report to Commissioner B2; US 7,211,267 B2; 5,789,395; 5,919,775; (ksr) (Entered: 09/21/2009) 18 September 2009 PACER… Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 7,232,572 B2…2009 9 August 2012 1:09-cv-00703 830 Patent None District Court, D. Delaware External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
McKinsey
Boehringer Ingelheim
Medtronic
Harvard Business School
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.